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Caveolae are fl   ask-shaped invaginated mem-
brane vesicles with a diameter of 50–100 nm. 
They are characterized by the existence of a 
group of 22–24-kD integral membrane pro-
teins termed caveolins. Among the three cave-
olins identifi  ed to date, caveolin-1 (cav-1) is 
the most extensively characterized and is re-
garded as the biochemical marker of caveolae 
in many cell types (1). It forms a high molecu-
lar complex and interacts with cav-2 (2). The 
most abundant cav-1–expressing cells are fi  -
broblasts, endothelial cells, type I pneumocytes, 
and adipocytes (3). cav-3 expression is restricted 
to muscle cells (4). Many cellular functions 
have been attributed to caveolae and cav-1, 
  including membrane traffi   cking,  endocytosis, 
regulation of calcium homeostasis, lipid me-
tabolism, and signal transduction in cellular 
proliferation and apoptosis (1). Because of the 
distinctive lipid composition (rich in glyco-
sphingolipids, sphingomyelin, and cholesterol), 
caveolae function to concentrate many lipid-
attached signal molecules into one specialized 
membrane organelle. cav-1, the scaff  olding pro-
tein of caveolae, interacts with many signal-
ing molecules and regulates their activation (5). 
For example, cav-1 inhibits the activation of 
growth factor receptors, such as the epidermal 
growth factor receptor (6) and the platelet-
  derived growth factor receptor (7), and the 
downstream mitogen-activated protein kinase 
(MAPK) and phosphoinositide 3–kinase path-
ways, resulting in reduced cell growth and in-
creased apoptosis.
Idiopathic pulmonary fi  brosis (IPF) is a pro-
gressive chronic interstitial lung disease with a 
high mortality (median survival of newly di-
agnosed patients is  3 yr) and uniformly poor 
prognosis (8). The pathogenesis of IPF is still 
poorly understood. Current medical therapies, 
such as corticosteroids, cytotoxic drugs, and 
IFN-γ, have been based on attempts to sup-
press the infl  ammatory and fi  brotic process but 
have thus far off  ered little benefi  t against the 
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  patients with pulmonary fi  brosis.
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Figure 1.  Altered cav-1 expressions in IPF patients. (A) Microarray 
analysis of cav-1 mRNA reveals a signifi  cant reduction (P = 0.000087, 
fold 0.5) in IPF patients (n = 13) compared with controls (n = 11). Boxes 
indicate the middle two quartile values, with the median values shown. 
Error bars represent 1.5× the interquartile range. (B) Immunohisto-
chemical analysis of cav-1 expression in lung tissue sections (cav-1, 
green; nucleus, blue; α-SMA, orange). One representative example out 
of seven for patient sample or control subjects is shown. Bar, 100 μm. 
Immunohistochemical analysis of cytokeratin 19 (C) and CD31 (D) and 
cav-1 expression in normal (CTL) and IPF lung tissue sections. One repre-
sentative example out of three for patient sample or control subjects 
is shown. Bars: (C) 50 μm; (D) 100 μm. (E) cav-1 protein expressions 
as detected by immunoblot analysis in lung tissue samples from IPF 
patients (n = 7) and control subjects (n = 7). Three representative 
  samples of patients and controls are shown. White lines indicate that 
intervening lanes have been spliced out. (F) cav-1 mRNA expressions 
were detected by Taqman PCR in pulmonary fi  broblasts derived from IPF 
patients (n = 4) and control subjects (n = 5). (G) cav-1 and β-actin 
protein expressions were determined by immunoblot analysis in pulmo-
nary fibroblasts derived from IPF patients (n = 4) and control subjects 
(n = 5). Three representative patients and control samples are shown. 
The differences in mRNA level of cav-1 expression were compared by the 
Student’s t test. The differences in protein levels of cav-1 expression 
were compared by the Wilcoxon two-sample test. Differences were con-
sidered signifi  cant at P < 0.05. Data in E–G represent the mean ± SEM. 
CTL, control.JEM VOL. 203, December 25, 2006  2897
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progression of the disease (9, 10). Although there is no known 
etiologic stimulus that initiates IPF, many investigators be-
lieve that endogenous and exogenous stimuli may injure the 
alveolar epithelium, followed by an abnormal   repair process 
(11), including aberrant cytokines and growth factor produc-
tion (10). TGF-β1 has been implicated as one of the media-
tors in the initiation and progression of fi  brosis (12). TGF-β1 
initiates the signal by binding to TGF-βRI and TGF-βRII. 
The binding activates serine/threonine kinases of TGF-βR 
complexes, which phosphorylate the immediate eff  ectors, 
smad-2/3. After phosphorylation, the conformation of smad-
2/3 changes thereby facilitates the binding with smad-4. The 
smad complex then translocates into the nucleus, where it 
acts to modulate the extracellular matrix (ECM) gene tran-
scription. A variety of molecules are reported to regulate the 
TGF-β signaling, including the extracellular signal–regulated 
protein kinase (ERK)–MAPK pathway, IFN-γ, and the in-
hibitory protein, smad-7, which directly interacts with the 
receptor and inhibits the signaling (12).
Recently, cav-1 expression was demonstrated to be 
abnormal in experimental models of pulmonary fi  brosis. 
Tourkina et al. found that cav-1 expression was low in bleo-
mycin (BLM)-induced lung fi  brosis tissue (13). Kasper et al. 
reported that cav-1 expression decreased with the treatment 
of CdCl2 and TGF-β1 in rat lung slices in vitro (14). They 
also observed that type I pneumocytes lost their cav-1 ex-
pression in early stages in a rat model of irradiation-induced 
lung injury (15). BLM, the drug inducing pulmonary fi  brosis 
in vivo, decreased cav-1 expression in cultured rat epithelial 
cells (16). Moreover, cav-1 has been implicated to associate 
with TGF-βRs in human endothelial cells (17). cav-1 also 
inhibits the phosphorylation of smad-2, disrupting its interac-
tion with smad-4, and prevents nucleus translocation of the 
smad-2 complex via the scaff  olding domain of cav-1 in the 
mouse fi  broblast NIH3T3 (18). Together with the studies of 
cav-1 knockout mice, which develop lung fi  brosis (19), we 
hypothesize that cav-1 plays a pivotal role in regulation of 
ECM production, and treatment increasing cav-1 expression 
might suppress the pathogenesis of pulmonary fi  brosis.
In this study, we tested our hypothesis in several indepen-
dent ways. We extensively investigated cav-1 expression in 
lung tissue and fi  broblasts from IPF patients and control 
  subjects. We report for the fi  rst time that cav-1 confers anti-
fi  brotic eff  ects both in vitro and in vivo. Our data suggest 
that cav-1 is an important regulator in the pathogenesis of 
pulmonary fi  brosis and a promising molecular target in the 
therapy for pulmonary fi  brosis.
RESULTS
Altered expression of cav-1 in lungs of IPF patients
Given the reduced cav-1 expression in samples from experi-
mental pulmonary fi  brosis that has been previously reported 
(13–15), we determined whether expression of cav-1 was al-
tered in patients with IPF. We analyzed cav-1 expression in a 
previously described gene-profi  ling dataset of IPF (20) and ob-
served a twofold reduction in cav-1 mRNA in IPF lung tissues 
(P = 0.000087; Fig. 1 A). A similar decrease was found in an-
other dataset (21) that we recently published. The reduction of 
cav-1 protein expression was confi   rmed by immunohisto-
chemistry staining (Fig. 1 B) and quantifi  ed by densitometric 
analysis of immunoblots (Fig. 1 E). Among the 14 lung tissue 
samples examined (7 IPF patients and 7 control subjects), the 
mean cav-1 expression decreased by  73% in IPF patients 
compared with the controls (P = 0.035), as measured by the 
ratio of band densitometric units of cav-1 to β-actin.
To determine cell type–specifi  c loss of cav-1 expression 
in the IPF lung, we performed double  immunohistochemistry 
staining of cav-1 with CD31 or cytokeratin 19. As demon-
strated in Fig. 1 C, the cells positive for cytokeratin 19, which 
is known as an epithelial cell marker, showed a markedly 
  decreased cav-1 expression compared with normal tissue, 
whereas the cells positive for CD31, which is known as an 
endothelial cell marker, demonstrated no reduction of cav-1 
levels compared with control tissue (Fig. 1 D).
We next examined cav-1 expression in pulmonary fi  -
broblasts by Taqman RT-PCR and immunoblot analysis. 
A marked reduction of cav-1 mRNA level was observed 
in pulmonary fi  broblasts derived from IPF patients (n = 4) 
compared with control subjects (n = 5; Fig. 1 F). Similarly, 
cav-1 protein expression was also decreased signifi  cantly 
in IPF (n = 4) compared with control (n = 5) fi  broblasts 
(P = 0.014; Fig. 1 G).
cav-1 gene transfer via adenovirus suppresses 
BLM-induced pulmonary fi  brosis
To better understand the function of cav-1 in the fi  brotic 
process, we tested the regulatory eff  ects of cav-1 on BLM-
induced pulmonary fi  brosis in vivo. We constructed an ade-
novirus vector, which eff  ectively transferred the cav-1 gene 
into the lung tissue by intratracheal instillation (Fig. S1, available 
at http://www.jem.org/cgi/content/full/jem.20061536/DC1). 
The mice were infected with ad–cav-1, ad-lacZ, or saline 
2 d before BLM or saline administration. Lung tissue was har-
vested 2 wk after injury and subjected to a variety of analyses.
For groups without BLM treatment, alveolar architec-
ture was preserved (Fig. 2, A and B; and Fig. S2, available 
at http://www.jem.org/cgi/content/full/jem.20061536/
DC1). No signifi  cant diff  erences were observed among the 
saline, ad-lacZ, and ad–cav-1 groups (mean fi  brosis scores: 
0.12 ± 0.12, 0.49 ± 0.43, and 0.56 ± 0.06, respectively; 
P = 0.162; Fig. 2 C). Similarly, collagen accumulation, an 
index of lung fi  brosis as determined by the measurement of 
hydroxyproline content, was basally low in these controls 
(111.58 ± 18.9, 133.6 ± 24.2, and 144.2 ± 27.7 μg, respec-
tively; P = 0.1987; Fig. 2 D). Consistently, immunoblots of 
the homogenized protein of lung tissue demonstrated low 
basal ECM production and undetectable smad-2 activation 
(Fig. 2 E). TGF-β1, one of the key cytokines involved in 
pulmonary fi  brosis (12), was observed to have low basal levels 
by ELISA in all three groups (Fig. 2 F).
In contrast, for groups with BLM treatment, lung tissue 
sections in both saline- and ad-lacZ–instilled groups showed 2898  CAVEOLIN-1 INHIBITS EXTRACELLULAR MATRIX PRODUCTION | Wang et al.
extensive patchy areas of regional interstitial fi  brosis with 
marked disruption of the alveolar unit, increased thicken-
ing of the interstitium, and infl  ammation. However, in the 
ad–cav-1 group, the structural integrity of the lung was less 
severely aff  ected, with less evidence of fi  brotic obliteration, 
destruction of alveolar units, and infl  ammation cell infi  ltra-
tion (Fig. 2, A and B; and Fig. S2). The mean fi  brosis score 
was signifi  cantly reduced in the ad–cav-1 group compared 
with the lacZ and saline groups (2.83 ± 0.85, 2.18 ± 0.7, 
and 0.52 ± 0.45 in the saline, ad-lacZ, and ad–cav-1 groups, 
respectively; P = 0.0056 overall; P = 0.0009 for lacZ 
and cav-1; Fig. 2 C). The hydroxyproline content was in-
creased after BLM treatment in both the saline and ad-lacZ 
groups, whereas the ad–cav-1 group had a markedly reduced 
Figure 2.  cav-1 suppresses BLM-induced pulmonary fi  brosis. The 
C57BL/6 mice infected with ad–cav-1, ad-lacZ, or saline were treated 
with BLM for 14 d. The lungs were harvested and subjected to (A) H&E 
staining and (B) Masson trichrome staining of the right lung tissue. 
One representative example out of four or fi  ve is shown for each 
group in A and B. Bars, 200 μm. (C) Histology grade score analysis of 
the   tissue sections (n = 4 and 5 for groups without and with BLM, 
respectively). (D) Hydroxyproline content determination of the left lung 
(n = 4 and 5 for groups without and with BLM, respectively). Data in 
C and D represent the mean ± SEM. (E) ECM deposition and smad-2 
activation in the whole lung as determined by immunoblot analysis. 
(F) TGF-β1 content determination by ELISA of the homogenized protein 
of the whole lung (n = 3 for each group). (G) Hydroxyproline content 
determination of the whole lung 7 d after ad–cav-1 infection and 14 d 
after BLM instillation (n = 3 for each group). Data in F and G represent 
the mean ± SEM.JEM VOL. 203, December 25, 2006  2899
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hydroxyproline level (226.1 ± 29.7, 226.8 ± 8.2, and 178.4 
± 19.7 μg in the saline, ad-lacZ, and ad–cav-1 groups, re-
spectively; P = 0.0048 overall; P = 0.001 for lacZ and cav-1; 
Fig. 2 D). Furthermore, immunoblot analysis revealed that 
ad–cav-1 treatment dramatically suppressed fi  bronectin and 
collagen deposition compared with the lacZ group (Fig. 2 E). 
As expected, TGF-β1 also increased with the development 
of fi  brosis after BLM administration in both the saline and 
ad-lacZ groups, whereas it was signifi  cantly decreased in the 
ad–cav-1 infection group (Fig. 2 F). The smad-2 phosphory-
lation induced by BLM was also markedly diminished by 
ad–cav-1 infection (Fig. 2 E).
To explore the therapeutic potentials of ad–cav-1, we in-
fected the mice with ad–cav-1 or ad-lacZ 7 d after BLM 
  instillation. 1 wk later, the whole lung was subjected to 
  hydroxyproline content determination. As shown in Fig. 2 G, 
ad–cav-1 infection suppressed hybroxyproline deposition 
compared with ad-lacZ infected mice (400.4 ± 51.1 and 
208.9 ± 28.4 μg in the ad-lacZ and ad–cav-1 groups, respec-
tively; P = 0.0048; Fig. 2 G).
TGF-𝗃1 regulates cav-1 expression in pulmonary fi  broblasts
TGF-β1 is one of the key cytokines involved in pulmonary 
fi  brosis (12). Its level, contrary to cav-1 expression, increases 
considerably in active fi  brotic areas (12), which leads to the 
hypothesis that TGF-β1 might be one of the negative regula-
tors of cav-1 expression. To test this hypothesis, we adminis-
tered TGF-β1 to human primary pulmonary fi  broblasts and 
MRC-5, a human pulmonary fi  broblast cell type, and ana-
lyzed the expression of cav-1. As detected by Taqman RT-
PCR, mRNA of cav-1 markedly decreased in primary 
fi  broblasts (P = 0.0024) and in MRC-5 (P = 0.0002; Fig. 
3 A) after 1 d of treatment with TGF-β1. We also observed 
decreased cav-1 protein levels after TGF-β1 treatment in a 
time- and dose-dependent manner (Fig. 3, B and C).
cav-1 suppresses TGF-𝗃1–induced ECM production 
in pulmonary fi  broblasts
To delineate the mechanism of the antifi  brotic eff  ects of cav-1 
observed in the in vivo studies (Fig. 2), we used an in vitro 
model to test the eff  ects of cav-1 on TGF-β1–induced ECM 
production with both gain of function and loss of function 
experiments. Three independent experiments were shown 
for each condition (one representative is shown in Fig. 4; 
see Fig. S4 for the other two). Densitometric quantifi  cation 
and statistical analysis were performed. For gain of function 
experiments, we used the ad–cav-1 to up-regulate cav-1 
  expression in MRC-5. cav-1 expression markedly increased 
in a dose-dependent manner after ad–cav-1 infection (Fig. 
S3 A, available at http://www.jem.org/cgi/content/full/
jem.20061536/DC1), which lasted until the fourth day with 
optimal cav-1 expression at 2 d after infection (Fig. S3 B). 
Using this adenovirus, we found that overexpressing cav-1 
signifi  cantly suppressed the TGF-β1–induced ECM produc-
tion, including collagen type I and fi  bronectin (Fig. 4 A and 
Fig. S4 A). It also inhibited fi  broblast activation, indicated by 
α–smooth muscle actin (α-SMA) production (Fig. 4 A and 
Fig. S4 A) (22). This observation was further confi  rmed in 
MRC-5 cells that were stably transfected with the cav-1 gene. 
Likewise, the production of collagen type I, fi  bronectin, and 
α-SMA stimulated by TGF-β1 were markedly reduced by 
cav-1 stable transfection compared with the vector- transfected 
control cells (Fig. 4 B and Fig. S4 B). We also performed loss 
of function experiments by transfection of siRNA targeting 
human cav-1, which eff  ectively reduced cav-1 expression 
(Fig. S3 C). Importantly, down-regulation of cav-1 markedly 
enhanced the TGF-β1–induced productions of α-SMA, 
  collagen type I, and fi  bronectin (Fig. 4 C and Fig. S4 C). 
Under nonstimulated conditions, the eff  ects of cav-1 on fi  bro-
nectin, collagen type I, and α-SMA production were not 
statistically signifi  cant (Fig. 4) with the exception of collagen 
type I production in MRC-5 stably transfected with the cav-1 
gene (P < 0.05; Fig. 4 B).
cav-1 modulates TGF-𝗃1–induced smad signaling
To investigate the molecular mechanism of antifi  brotic eff  ects 
of cav-1, we determined the regulation of smad activation by 
cav-1 in MRC-5 with both gain and loss of function experi-
ments. Overexpression of cav-1 in ad–cav-1–infected MRC-5 
suppressed smad-2 phosphorylation and nucleus translocation. 
It also eff   ectively attenuated smad-3 nucleus translocation 
while having negligible eff  ects on smad-4/7 expression and 
smad-4 nucleus translocation (Fig. 5 A). Down-regulation of 
cav-1 by siRNA transfection increased smad-2 phosphoryla-
tion and smad-2/3 nucleus translocation (Fig. 5 B).
Figure 3.  TGF-𝗃1 regulates cav-1 expression. (A) Human primary 
pulmonary fi  broblasts and MRC-5 cells were treated with 4 ng/ml TGF-β1 
for 24 h. cav-1 mRNA levels were determined by Taqman PCR. Data repre-
sent the mean ± SEM. (B) The same cells were treated with different con-
centrations of TGF-β1 for 24 h (C) or treated with 4 ng/ml TGF-β1 for 
1 and 2 d. cav-1 protein levels were determined by immunoblot analysis. 
Data are representative of three independent experiments.2900  CAVEOLIN-1 INHIBITS EXTRACELLULAR MATRIX PRODUCTION | Wang et al.
cav-1 modulates TGF-𝗃1–induced ECM production 
via the c-Jun N-terminal kinase (JNK) pathway
MAPK pathways are reported to regulate TGF-β1 signal-
ing and TGF-β1–induced ECM production by many inves-
tigators (23, 24). cav-1 has been shown to modulate MAPK 
activation in mesangial cells (25) and macrophages (26). In 
this paper, we hypothesized that cav-1 might regulate TGF-
β1–induced ECM production via MAPK pathways in human 
lung fi  broblasts. As demonstrated in Fig. 6 A, overexpressing 
cav-1 via ad–cav-1 substantially inhibited TGF-β1–induced 
ERK and JNK activation. There was no apparent induction 
of p38 phosphorylation by TGF-β1 in MRC-5. The involve-
ment of ERK and JNK pathways was further explored using 
chemical inhibitors. Overexpressing cav-1 inhibited TGF-
β1–induced ECM production in DMSO samples. In con-
trast, PD 98059 (an inhibitor of MEK1 and an upstream 
  kinase of ERK) and UO 126 (an inhibitor of MEK1/2 and 
an upstream kinase of ERK) administration abolished the 
modulation of cav-1 on collagen type I production while 
having a negligible eff   ect on fi   bronectin production (Fig. 
6 B). On the other hand, SP 600125 (a JNK1/2 inhibitor), 
eliminated the modulation of cav-1 on fi  bronectin produc-
tion while having less eff  ect on collagen type I modulation 
(Fig. 6 B). Furthermore, pulmonary fi  broblasts isolated from 
Figure 4.  cav-1 modulates TGF-𝗃1–induced ECM productions. 
(A) After adenovirus infection, 4 ng/ml TGF-β1 was added into MRC-5 
for 2 d. ECM productions were determined by immunoblot analysis. 
(B) ECM productions in cav-1 stably transfected and control MRC-5 cells 
after 2 d of 4-ng/ml TGF-β1 treatment. (C) After siRNA transfection for 
24 h, the MRC-5 cells were serum-starved overnight and treated with 
4 ng/ml TGF-β1 for 2 d. ECM productions were determined by immuno-
blot analysis. Three independent experiments were performed, and one 
representative sample is shown. The differences in densitometric quanti-
fi  cation of cav-1 expression were compared by the Student’s t test. 
Differences were considered signifi  cant at P < 0.05. Data represent 
the mean ± SEM.JEM VOL. 203, December 25, 2006  2901
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JNK1-null mice did not exhibit diff  erences in TGF-β1–
  stimulated fi   bronectin production between ad-lacZ and 
ad–cav-1 infection compared with the fi  broblasts  isolated 
from JNK1 wild-type littermates (Fig. 6 C). These data sug-
gest that cav-1 modulates TGF-β1–induced collagen type I 
production via the ERK1 pathway while modulating TGF-
β1–induced fi  bronectin production via the JNK1 pathway.
JNK1-null mouse fi  broblasts showed similar suppressions 
of smad-2 phosphorylation and smad-2/3 nucleus transloca-
tion, mimicking the eff  ects of overexpressing cav-1 (Fig. 6 D), 
suggesting that cav-1 regulates smad-2/3 activation via the 
JNK1 pathway. To clarify this hypothesis, cav-1 was over-
expressed in JNK1 wild-type and null fi  broblasts by adeno-
virus infection. As expected, cav-1 markedly suppressed 
smad-2 phosphorylation and smad-2/3 nucleus translocation 
in wild-type fi  broblasts (Fig. 6 E). Meanwhile, in JNK1-null 
fi  broblasts, overexpressing cav-1 did not reduce smad-2 phos-
phorylation and nucleus translocation, whereas it still suppressed 
smad-3 nucleus translocation (Fig. 6 E).
To further investigate the role of JNK in vivo, we per-
formed immunochemical analysis with the BLM-treated 
lung fi  brosis tissue. As shown in Fig. 6 F, the phosphorylated 
JNK level was dramatically high in saline and lacZ mice, 
whereas ad–cav-1 infection markedly attenuated phospho-
JNK. Moreover, JNK was highly activated in IPF tissues 
compared with the controls (Fig. 6 G), indicating its pivotal 
role in IPF development.
D  I  S  C  U  S  S  I  O  N 
Because IPF shows a distinct histopathology of usual intersti-
tial pneumonia, a commonly held view is that persistent inter-
stitial infl  ammation leads to and modulates the development 
of fi  brosis (27). This hypothesis is applied in clinical settings 
in that antiinfl  ammatory therapies combined with immuno-
suppressive therapy are major strategies used in treating IPF. 
However, the outcome is still poor (11). A recent hypothesis 
has been advanced by Selman et al. and others that IPF is an 
epithelial-fi  broblastic disease (28). Alveolar epithelial cell in-
jury and activation will release many fi  brogenic mediators, 
which lead to the transformation of fi  broblasts to myofi  bro-
blasts and the formation of fi  broblast-myofi  broblast foci that 
is characterized by fi  broblast-myofi  broblast migration and pro-
liferation, decreased apoptosis, and enhanced release of fi  bro-
genic growth factors (e.g., TGF-β1) (28).
We observed that cav-1 was highly expressed in epithelial 
and endothelial cells in the normal lung, whereas in the IPF 
lung the cav-1 levels were reduced dramatically in epithelial 
cells, as evident by the immunohistochemical analysis. We 
noticed that reduced levels of cav-1 occurred in areas with 
minimal α-SMA staining. Together with a previous report 
that reduced cav-1 expression occurred at early stages of 
  irradiation-induced pulmonary fi  brosis in a rat model, when 
no apparent histopathology changes were observed (15), we 
hypothesized that the decreased cav-1 level might be an early 
event and indicator of the impaired cellular functions of epi-
thelial cells in the initiation of IPF pathogenesis. However, 
we do not rule out the possibility that this phenomena also 
happens in later stages of fi  brosis. The expression of cav-1 was 
also considerably reduced in fi  broblasts derived from IPF 
  patients. Interestingly, lung fi  broblasts isolated from scleroderma 
patients with pulmonary fi  brosis also showed a decreased 
expression of cav-1 (13), suggesting that the reduced cav-1 
level occurs in other pulmonary fi  brotic disorders, such as 
scleroderma. Consistent with the reduced cav-1 level in IPF, 
myofi  broblasts were reported to be lacking caveolae, as re-
vealed by electron microscopy (29). Consequently, decreased 
cav-1 levels might lead to hyperactive TGF-β1 signaling in 
fi  broblasts and increased TGF-β1 secretion. The expression 
of mRNA was in accordance with the protein level, suggest-
ing that cav-1 is primarily regulated at the transcriptional level. 
We noticed the standard deviation of cav-1 expression in 
control samples was high, which can be explained by the wide 
range of individual variance. However, cav-1 expression in 
Figure 5.  cav-1 modulates smad activation. Immunoblot analysis of 
smad-2 phosphorylation; smad-4 and smad-7 expressions in cytosolic 
extracts; and smad-2/3 and smad-4 existences in nuclear extracts under 
different conditions in MRC-5. (A) Cells were infected with ad–cav-1 
and ad-lacZ and (B) transfected with siRNA targeting cav-1 and control 
for 24 h. The cells were serum-starved overnight and treated with 
TGF-β1 for 0, 10, 30, and 60 min. Data are representative of three 
indepen dent  experiments.2902  CAVEOLIN-1 INHIBITS EXTRACELLULAR MATRIX PRODUCTION | Wang et al.
IPF samples was consistently low with a narrow range of 
  variance. We found that TGF-β1 markedly decreased cav-1 
expression in a dose- and time-dependent manner in human 
pulmonary fi  broblasts, whereas TGF-β1 was demonstrated to 
be produced at the sites of active fi  brosis, and its level in the 
lung was reported to be proportionate to the degree of fi  brosis 
generated (12). Therefore, the increased levels of TGF-β1 
might contribute to the cell type–specifi  c attenuation of cav-1 
expression in lung tissues of IPF patients.
IPF is a disease with substantially high morbidity and 
mortality. To date, no eff  ective approaches are available to 
reverse the development of pulmonary fi  brosis. In this study, 
we found that cav-1, the caveolae marker protein involved in 
many signal pathways, shows promise for slowing the pro-
gression of pulmonary fi  brosis. In the BLM-induced pul-
monary fi  brosis model in vivo, overexpression of cav-1 by 
adenoviral gene transfer strikingly diminished the lung fi  bro-
sis scores and hydroxyproline content compared with lacZ 
virus, accomplished by attenuated collagen deposition, re-
duced fi  bronectin production, less TGF-β1 secretion, and 
smad-2 phosphorylation. Moreover, we infected the mice 
with ad–cav-1 7 d after BLM injury, when the fi  brosis was 
already initiated and minor lung injury can be detected (30). 
cav-1 was still able to suppress the fi  brosis development, as 
Figure 6.  MAPK pathways are involved in ECM regulation of cav-1. 
(A) Immunoblot analysis of TGF-β1–stimulated MAPK activation for 
0, 10, 30, and 60 min in MRC-5 cells infected with ad–cav-1 or ad-lacZ. 
(B) Immunoblot analysis of TGF-β1–stimulated ECM production in MRC-5 
cells infected with ad–cav-1 or ad-lacZ. The cells were pretreated with 
DMSO or PD 98059, or UO 126 or SP 600125 for 1 h, and administrated 
with TGF-β1 for 2 d. (C) Immunoblot analysis of TGF-β1–stimulated ECM 
production in pulmonary fi  broblasts isolated from JNK1 (+/+) and (−/−) 
mice infected with ad–cav-1 or ad-lacZ. (D) Immunoblot analysis of 
smad-2 phosphorylation in cytosolic extracts and smad-2/3 existences in 
nuclear extracts. (E) Immunoblot analysis of smad-2 phosphorylation in 
cytosolic extracts and smad-2/3 existences in nuclear extracts in JNK1 
wild-type and null fi  broblasts infected with ad–cav-1 or ad-lacZ. Data are 
representative of three independent experiments in A–E. (F) Immunohisto-
chemical analysis of JNK phosphorylation in paraffi  n-embedded lung 
tissue slices treated with BLM and infected with ad-lacZ or ad–cav-1 or 
instilled with saline. Brown indicates phospho-JNK–positive cells. One 
representative example out of fi  ve is shown. Bar, 100 μm. (G) Immunohisto-
chemical analysis of JNK phosphorylation in frozen lung tissue slices from 
IPF patients and control subjects (phospho-JNK, green; nucleus, blue). One 
representative example out of seven for patients or controls is shown. Bar, 
100 μm.JEM VOL. 203, December 25, 2006  2903
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demonstrated by the reduction of the hydroxyproline deposi-
tion. As we noticed, the reduction of hydroxyproline content 
in the left lung was not as impressive as histology examina-
tion scores of the right lung. This might be caused by the low 
sensitivity of the assay or uneven distribution of the virus and 
BLM in the left and right lung, which is associated with in-
tratracheal administration through the mouth into asymmet-
ric lungs of mice.
TGF-β1 is a major pivotal fi  brogenic factor involved in 
IPF (22). It promotes myofi  broblast transformation, which 
is responsible for secreting large amount of ECM, and pres-
ents only in fi  brotic lung tissue but not in normal lung tissue 
(22). It suppresses ECM degradation through the regulation 
of matrix metalloproteases and their inhibitors (31). TGF-β1 
causes minor infl  ammation but marked progressive fi  brosis 
in the lung. It has many diverse functions, including che-
moattractant and mitogenic activities and the regulation of 
lung infl  ammation and functions of epithelial cells, which 
further aff  ect the fi  brotic process through autocrine or para-
crine mechanisms (12). Transfer of the TGF-β1 gene into rat 
lungs via an adenoviral vector can induce a severe and pro-
gressive lung fi  brosis (32). Blocking TGF-β1 can eff  ectively 
reduce the fi  brosis in diff  erent animal models (12). Inhibition 
of TGF-β1 signaling was capable of slowing the progression 
of IPF when administered to patients (33). In this paper, us-
ing several independent and complementary approaches, we 
demonstrated that cav-1 modulated TGF-β1 signaling and 
that it induced ECM productions, including collagen type I 
and fi  bronectin in human pulmonary fi  broblasts. We chose 
the TGF-β1 stimulation fi  brosis model instead of the un-
stimulated state because that was more similar to the patho-
logical and physiological conditions in pulmonary fi  brosis 
development. It was recently reported that inhibition of 
cav-1 expression by siRNA increased baseline collagen ac-
cumulation in normal lung fi  broblasts (13). Our results show 
that the changing cav-1 expression does not signifi  cantly af-
fect baseline fi  bronectin, collagen, and α−SMA production 
in MRC-5. The only signifi  cant baseline change was that 
cav-1 stably transfected MRC-5 had less collagen type I ac-
cumulation. Note that although the baseline level of collagen 
type I was reduced by cav-1 stable transfection, cav-1 more 
dramatically attenuated ECM accumulations in the TGF-β1–
stimulated state.
Given the previous report that cav-1 interacted with 
TGF-βRI and transfection of a HA-tag cav-1–inhibited 
smad-2 phosphorylation in NIH3T3 cells (18), we postulated 
that cav-1 might modulate smad activity. The eff  ect of cav-1 
on smad-3, -4, and -7 has not, to our knowledge, previously 
been examined. Using adenovirus and siRNA transfection, 
cav-1 was demonstrated to suppress TGF-β1–induced smad-2 
phosphorylation, similar to the earlier studies (18). cav-1 was 
also found to suppress smad-3 nucleus translocation but had 
no apparent eff  ects on smad-4/7 expression.
The family of MAPKs consists of three known subfami-
lies, including ERK1/2, JNK1/2, and p38. These MAPKs 
have been reported to regulate TGF-β1–induced ECM pro-
duction and pulmonary fi  brosis (20, 21), greatly depending 
on the cell types and experimental conditions. We examined 
the role of the MAPK signaling cascades in mediating the ef-
fect of cav-1 on collagen and fi  bronectin synthesis. In the 
present studies, ERK and JNK were induced rapidly by 
TGF-β1, whereas p38 seemed to have no apparent  induction. 
Up-regulation of cav-1 by adenoviral infection markedly 
attenuated the ERK and JNK phosphorylation, especially 
JNK phosphorylation 10 min after treatment. cav-1 has been 
demonstrated to regulate ERK1/2 activation in a variety of 
cells (1, 5, 6). It has also been shown that ERK localizes in 
caveolae and directly interacts with cav-1 (6). With respect to 
ECM regulation, we fi  nd that inhibiting ERK1 or ERK1/2 
selectively blocks the reduction eff  ects of cav-1 on collagen 
type I but not fi  bronectin production. These data were con-
sistent with previous fi  ndings that ERK1/2 regulated colla-
gen expression in pulmonary and dermal fi  broblasts (34, 35), 
and that ERK1/2 mediated cav-1 modulation of collagen 
type I production in nonstimulated states (13).
Interestingly, inhibition of the JNK pathway by the 
chemical inhibitor SP 600125 or genetic knockout selectively 
blocks the reduction eff  ects of cav-1 on fi  bronectin produc-
tion but not collagen type I. In a human fi  brosarcoma cell 
line, a similar fi  nding was reported that JNK activation was 
essential for TGF-β1–stimulated fi  bronectin production, as 
stable transfection of the dominant-negative mutant of JNK1 
had markedly suppressed TGF-β1–stimulated fi  bronectin 
mRNA and protein expression (36). Further investigation 
using JNK1-null fi  broblasts demonstrated the same reduced 
smad-2 phosphorylation and decreased smad-2/3 nucleus 
translocations compared with the wild-type fi  broblasts. In 
JNK1-null cells, cav-1 lost the ability to suppress smad-2 acti-
vation, while it was still capable of inhibiting smad-3 activation. 
Moreover, phospho-JNK staining was markedly reduced in 
ad–cav-1–infected BLM- injured mice lung samples com-
pared with lacZ or saline samples. Together with the fact that 
JNK was highly activated in IPF lung tissues, our data indi-
cate that cav-1 regulates TGF-β1–induced fi  bronectin pro-
duction via the JNK pathway, possibly via the modulation of 
smad-2 phosphorylation and nucleus translocation (Fig. 7).
In summary, we have demonstrated that cav-1 is capable 
of inhibiting the production of matrix molecules by fi  bro-
blasts, and exogenous transfer of cav-1 can inhibit the pul-
monary fi  brotic response in a BLM rodent model. We have 
also shown that cav-1 inhibited TGF-β1–induced collagen 
type I production via the ERK pathway and fi  bronectin pro-
duction via JNK pathway. We found that cav-1 mRNA and 
protein expression were low in the lung tissues and fi  bro-
blasts of IPF patients. We postulate that one of the mecha-
nisms for the phenomenon is through TGF-β1, which was 
shown to be an eff  ective regulator of cav-1 expression in 
pulmonary fi  broblasts. We delineated that the inhibition of 
smad-2 activation was by the cav-1–regulated JNK pathway. 
Our study strongly supports a pivotal role for cav-1 in ECM 
regulation and suggests a novel therapeutic target for patients 
with pulmonary fi  brosis.2904  CAVEOLIN-1 INHIBITS EXTRACELLULAR MATRIX PRODUCTION | Wang et al.
MATERIALS AND METHODS
Tissues, cell cultures, animals, and reagents. This study was approved 
by the Institutional Review Board for Human Subject Research at the 
  University of Pittsburgh. Human lung tissues were obtained from the tissue 
bank and core facility at the University of Pittsburgh. Diagnosis of IPF was 
supported by history, physical examination, pulmonary function studies, 
chest high-resolution computed tomography, and bronchoalveolar lavage 
fi  ndings and corroborated by open lung biopsy. The morphologic diagnosis 
of IPF was based on typical microscopic fi  ndings consistent with usual 
  in  terstitial pneumonia. The patients fulfi  lled the criteria of the American 
Thoracic Society and European Respiratory Society (37). Age-, race-, and 
sex-matched control samples, including normal histology lung samples from 
patients with lung cancer, were obtained from the Pittsburgh Tissue Bank. 
Primary pulmonary fi  broblasts were derived from a subset of the lung tissues 
from IPF patients and controls that were used for immunoblot and micro-
array studies. The cells were maintained in 10% FBS DMEM with 50 μg/ml 
gentamicin. Primary pulmonary fi   broblasts were isolated from JNK1−/− 
mice and wild-type littermates, as previously described (38). Human fetal 
pulmonary fi  broblasts (MRC-5; American Type Culture Collection) were 
maintained in 10% FBS DMEM. MRC-5 cells were cotransfected (1:10) 
with pcDNA3.0 containing the neomycin selection marker, the expression 
vector pCAGGS containing cav-1 cDNA in the sense orientation, or with 
the pCAGGS control vector. Transfected cells were grown in 10% FBS 
DMEM containing 200 μg/ml G418. Cultures were maintained at 37°C in 
a humidifi  ed atmosphere of 5% CO2 and 95% air. Cell culture reagents were 
purchased from Invitrogen. The cells were serum starved before TGF-β1 
(R&D Systems) stimulation. TGF-β1 was reconstituted in 4 mM of sterile 
HCl containing 0.1% BSA. C57BL/6 mice were purchased from the Jackson 
Laboratory and acclimated for 1 wk before experiments. All animals were 
housed in accordance with guidelines from the American Association for 
Laboratory Animal Care and Research Protocols and were approved by the 
Animal Care and Use Committee of the University of Pittsburgh School of 
Medicine. 10 μM each of PD 98059, UO 126, and SP 600125 (Calbio-
chem) were dissolved in DMSO. Those reagents were added to the culture 
medium 1 h before other treatments.
cav-1 adenovirus construction and infection. cav-1 cDNA (provided 
by F. Galbiati, University of Pittsburgh, Pittsburgh, PA) was inserted into a 
pAdlox plasmid. cav-1 and lacZ adenovirus productions were performed by 
the Vector Core Facility at the University of Pittsburgh. For cell infection, 
2 × 105 MRC cells were cultured in sixwell plates and exposed to 2 × 107 
PFU of each virus in 1 ml of serum-free medium for 4 h. The cells were 
washed and incubated in serum-containing media for 36 h. The cells were 
subjected to other treatments as indicated in the fi  gure legends. For animal 
infection, 1011 virus particles of each virus in 50 μl of saline were adminis-
trated intratracheally per mouse.
BLM administration. After 2 d of adenovirus infection, the mice were 
lightly sedated with isofl  uorane. A dose of 3 U/kg BLM (Bristol-Myers 
Squibb) in 50 μl of sterile saline was administered intratracheally by canula-
tion of the trachea via the mouth with a 20-gauge feeding needle.
Histopathology. The right lungs were fi  xed in 10% formaldehyde for 24 h 
and processed for paraffi   n embedding. Sections of lung were stained with 
routine hematoxylin and eosin (H&E) or with a Masson trichrome stain to 
assess the degree of fi  brosis. The extent of lung fi  brosis was graded by a pa-
thologist (T.D. Oury) in a blinded manner on a scale of 0 (normal lung) 
to 4 as previously described (39, 40). The major criteria examined included 
interstitial thickening of alveolar or bronchiolar walls, collagen deposition, 
and infl  ammatory cell infi  ltration.
Hyproxyproline assay. After 14 d of BLM administration, the left lungs 
were harvested and dried at 110°C until a constant weight was obtained. 
For the therapeutic experiment, mice were infected with ad–cav-1 1 wk 
after BLM injury. The whole lung was harvested 1 wk later. The dried lung 
was hydrolyzed under vacuum in a glass vial containing 1 ml of 6 N HCl at 
110°C overnight. The samples were lyophilized and assayed for hydroxypro-
line content using a chloramine-T method, as previously described (39, 40).
TGF-𝗃1 determination. After diff   erent treatments with adenovirus 
and BLM as indicated in the preceding sections, the entire lung was harvested 
and homogenized as previously described (41). The levels of cytokine 
TGF-β1 were measured by ELISA kits (R&D Systems) according to the 
  manufacturer’s instructions.
Synthesis and transfection of siRNA. siRNA sequences targeting 
  human cav-1 gene (A  A  C  C  A  G  A  A  G  G  G  A  C  A  C  A  C  A  G  T  T  ) were synthe-
sized (Dharmacon, Inc.) (42). The sequence (A  A  C  G  C  G  C  A  C  A  C  C  A  A  G  G-
A  G  A  T  T  ) targeting the mice cav-1 gene with no apparent eff  ects in human 
cells was used as a negative control. For transfection, cells were plated on 
sixwell plates. Transfections were performed with TransIT-TKO reagent 
(Mirus Corp.), as directed by the manufacturer. Each well received 10 nM 
siRNA in a volume of 1 mL in triplicate. Other treatment was added after 
24 h of transfection.
Immunohistochemistry. In brief, lung tissues were fi  xed in 2% parafor-
maldehyde for 2 h and in 30% sucrose overnight. The tissues were frozen in 
liquid nitrogen and subjected to immunohistochemistry. The 6-μm tissue 
sections were washed three times in 0.5% BSA (Sigma-Aldrich) and blocked 
for 1 h in 2% BSA. After three washings of the samples in 0.5% BSA, tissue 
sections were incubated with the antibody specifi  c for cav-1 (Santa Cruz 
Biotechnology, Inc.), phospho-JNK (Cell Signaling Technology, Inc.), 
α-SMA (ARP American Research Products, Inc.), CD31 (Abcam), or cyto-
keratin 19 (Chemicon) for 1 h. The samples were washed fi  ve times in BSA 
and incubated with Cyr3 or an FITC 488–conjugated goat anti–rabbit Fab 
fragment (Jackson ImmunoResearch Laboratories) for 1 h. For mice samples, 
after fi  ve washings in BSA, the sections were incubated with the Alexa Fluor 
647 phalloidin (Invitrogen) for 1 h. Samples were washed fi  ve times in BSA 
and PBS. Hoechst dye (Sigma-Aldrich) was added for 30 s, and samples were 
washed in PBS and mounted. Tissue sections were viewed with a fl  uorescent 
microscope (BX51; Olympus). For paraffi   n-embedding lung samples, im-
munohistochemistry staining of phospho-JNK was performed as the manu-
facturer recommended (Cell Signaling Technology, Inc.).
Immunoblotting analysis. We performed an immunoblot analysis, as de-
scribed previously (26). Nuclear protein extracts were isolated as previously 
described (26). Immunoreactive bands were quantifi  ed using a molecular 
Figure 7.  Summary of the role of cav-1 in pulmonary fi  brosis. 
cav-1 modulates TGF-β1–induced JNK1 and smad-2/3 activity and inhibits 
α-SMA, fi  bronectin, and collagen type I production.JEM VOL. 203, December 25, 2006  2905
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image system (GS-525; Bio-Rad Laboratories). Specifi  c protein expression 
levels were normalized to the β-actin protein signal on the same nitrocellu-
lose membrane.
Oligonucleotide microarrays. The samples and methods for the genera-
tion of microarray data have been previously described (20). In brief, 13 
samples obtained from surgical remnants of biopsies or lungs explanted from 
patients with IPF that underwent pulmonary transplant and 11 normal his-
tology lung samples resected from patients with lung cancer were obtained 
from the tissue bank of the Department of Pathology at the University of 
Pittsburgh. Total RNA was extracted and used as a template to generate 
double-stranded cDNA and biotin-labeled cRNA, as recommended by the 
manufacturer of the arrays and previously described (20). Fragmented cRNA 
was hybridized to slides (CodeLink Uniset I; GE Healthcare). After hybrid-
ization, arrays were washed and stained with streptavidin–Alexa Fluor 647. 
The arrays were scanned using a microarray scanner (GenePix 4000B; 
  Molecular Devices). Images were analyzed using an analysis suite (CodeLink 
Expression II; GE Healthcare). They were visually inspected for defects and 
quality control parameters as recommended by the manufacturer. Data fi  les 
were imported into a microarray database, linked with updated gene annota-
tions using SOURCE (http://genome-www5.stanford.edu/cgi-bin/SMD/
source/sourceSearch), and median scaled. Based on our previous experience, 
all expression levels below 0.01 were brought to 0.01. The complete set of 
gene array data has been deposited in the National Center for Biotechnology 
Information Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo) under accession no. GSE2052, according to MIAME guidelines. The 
general approach to analysis was previously described (43).
Purifi  cation of RNA and quantitative RT-PCR. Total RNA was iso-
lated from cells with TRIzol reagent using the manufacturer’s protocol 
  (Invitrogen) and further purifi  ed with an RNeasy Mini kit (QIAGEN). The 
RT was performed using Superscript II (Invitrogen) according to manufac-
turer’s instructions. Isolated RNA was incubated with a random hexamer at 
65°C for 5 min for annealing. The optimal RT reaction was then performed 
in 20-μl volumes consisting of 1× RT buff  er, 1 μl of SuperScript II reverse 
transcriptase, 1 μl of RNaseOUT, 5 mM MgCl2, 0.5 mM dNTP, 0.01 mM 
DTT, 5 μmol/L of random hexamers, and 500 ng of total RNA. Reactions 
were incubated at 25°C for 10 min, 48°C for 30 min, and 95°C for 5 min. 
“No RT” controls were performed in all samples using the same RT reac-
tion mix but substituting DEPC-H2O for SuperScript II reverse transcrip-
tase. PCR primers, fl  uorogenic probes, and all other reagents were purchased 
from Applied Biosystems (human cav-1 and human β-glucuronidase) and 
used according to the manufacturer’s protocol. Quantitative RT-PCR was 
performed in triplicate in 40-μl reaction volumes consisting of 1× PCR 
buff  er A, 3.5 mM MgCl2, 0.3 mM dNTP, 0.025 U/μl of AmpliTaq Gold, 
and 4 μl of the RT reaction. Two-step PCR cycling was performed as 
  follows: 95°C for 12 min × 1 cycle, 95°C for 15 s, and 60°C for 1 min × 40 
cycles. At the end of the PCR, baseline and threshold values were set 
in software (ABI 7700 Prism; Applied Biosystems), and the relative cav-1 
expressions were calculated as previously described (44).
Statistical analysis. Statistical analysis of microarrays was performed using 
the ScoreGenes gene expression package (http://www.cs.huji.ac.il/labs/
compbio/scoregenes), and data visualization was performed using GeneX-
Press (http://genexpress.stanford.edu) and Spotfi   re DecisionSite (version 
8.0; Spotfi  re Inc.). p-values were calculated by multiple testing, as previ-
ously described (39). The diff  erences in mRNA and protein levels of cav-1 
expression in IPF and control samples were compared by the Wilcoxon 
two-sample test, because the data do not follow a normal distribution. The 
diff  erences in mRNA levels of cav-1 expression in MRC-5 cells deter-
mined by Taqman RT-PCR were compared by the Student’s t test, be-
cause the data follow a normal distribution. The normality of the dataset 
was tested by the Anderson-Darling goodness-of-fi  t test. For animal experi-
ments, diff  erences in measured variables between experimental and control 
groups were analyzed using analysis of variance (ANOVA). Groups con-
taining multiple comparisons were assessed by ANOVA, and Bonferroni’s 
correction was used in determining p-values. For statistical analysis of the 
densitometric quantifi  cation of in vitro ECM production, the Student’s 
t test was used, because the data follow a normal distribution. All analyses 
were performed with SPSS for Windows (version 12.0.1) and were consid-
ered signifi  cant at P < 0.05.
Online supplemental material. Fig. S1 shows the cav-1 gene expression 
in mouse lung tissue after ad–cav-1 infection. Fig. S2 shows the low magni-
fi  cation picture of H&E and Masson trichrome staining of lung sections in-
fected with ad–cav-1, ad-lacZ, or saline. Fig. S3 shows cav-1 expression in 
MRC-5 cells infected with ad–cav-1, stably transfected with cav-1 cDNA, 
or transfected with siRNA targeting cav-1. Fig. S4 shows the collagen type 
I, fi  bronectin, and α-SMA production in MRC-5 cells infected with 
ad–cav-1, stably transfected with cav-1 cDNA, or transfected with siRNA 
targeting cav-1. Online supplemental material is available at http://www.
jem.org/cgi/content/full/jem.20061536/DC1.
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